Granet-Vaissiere, E.; Lefort, F.; Domblides, C.; Larroquette, M.; Ravaud, A.; Bernhard, J.-C.; Gross-Goupil, M.
Combinations of Anti-Angiogenic Agents and Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Best Option? Cancers 2023, 15, 1048.
https://doi.org/10.3390/cancers15041048
AMA Style
Granet-Vaissiere E, Lefort F, Domblides C, Larroquette M, Ravaud A, Bernhard J-C, Gross-Goupil M.
Combinations of Anti-Angiogenic Agents and Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Best Option? Cancers. 2023; 15(4):1048.
https://doi.org/10.3390/cancers15041048
Chicago/Turabian Style
Granet-Vaissiere, Estelle, Félix Lefort, Charlotte Domblides, Mathieu Larroquette, Alain Ravaud, Jean-Christophe Bernhard, and Marine Gross-Goupil.
2023. "Combinations of Anti-Angiogenic Agents and Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Best Option?" Cancers 15, no. 4: 1048.
https://doi.org/10.3390/cancers15041048
APA Style
Granet-Vaissiere, E., Lefort, F., Domblides, C., Larroquette, M., Ravaud, A., Bernhard, J.-C., & Gross-Goupil, M.
(2023). Combinations of Anti-Angiogenic Agents and Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Best Option? Cancers, 15(4), 1048.
https://doi.org/10.3390/cancers15041048